Stuart L. Goldstein, MD, FAAP, FNKF
- Clark D. West Endowed Chair
- Director, Center for Acute Care Nephrology
- Medical Director, Pheresis Service
- Co-Director, Heart Institute Research Core
- Professor, UC Department of Pediatrics
- stuart.goldstein@cchmc.org
- Board Certified
About
Biography
As a pediatric kidney specialist, I treat children and adolescents in all areas of pediatric nephrology. These include general nephrology, acute kidney injury (AKI), dialysis, transplantation and tuberous sclerosis. I also consult on fetal care if there is a problem with the unborn baby’s kidneys.
I was drawn to the field of nephrology by the opportunity it presents to improve the outcomes for children with kidney problems. Working with children and their families, I help patients reach their full potential. Nephrology also allows me to practice across the entire spectrum of pediatric illness, from acute critical care, to chronic care and outpatient care.
My research is focused on short- and long-term outcomes for children who have AKI and those who are at risk for AKI. I’m interested in AKI epidemiology and outcomes, acute renal replacement therapy and investigation of novel urinary AKI biomarkers in the pediatric population.
In 2012, I established Prospective Pediatric AKI Research Group (ppAKI-RG). The ppAKI-RG is comprised of more than 60 centers around the world with the goal of improving outcomes for the child with, or at-risk for, AKI. This consortium focuses on multicentered research studies that are dedicated to understanding and treating AKI in pediatric patients. This group has completed three major, unprecedented national and international studies to accurately characterize pediatric AKI epidemiology, reduce AKI and improve patient outcomes.
I also developed the only pediatric-specific, acute-care nephrology subspecialty fellowship with graduates who are now leaders in the field of pediatric AKI.
MD: Columbia College of Physicians and Surgeons, New York, NY, 1990.
Residency: Baylor College of Medicine, Houston, TX.
Fellowship: Pediatric Nephrology, Children's Hospital, Boston, MA.
Interests
Acute kidney injury; continuous renal replacement therapy; cardio-renal syndrome; nephrotoxic medication associated morbidity
Interests
Acute kidney injury epidemiology and biomarkers; heart failure associated chronic kidney disease; nephrotoxic medication associated acute kidney injury reduction
Research Areas
Additional Languages
Spanish
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Projected hospitalization cost impact of the selective cytopheretic device in pediatric acute kidney injury. Journal of Medical Economics (JME). 2025; 28:1467-1475.
Urine Olfactomedin 4 Predicts Furosemide Response and Kidney Replacement Therapy in Critically Ill Children. Critical Care Explorations. 2025; 7:e1356.
Precision Dosing of Meropenem in a Neonate on CARPEDIEM Dialysis: A Grand Round. Therapeutic Drug Monitoring. 2025; 47:701-704.
Furosemide Stress Test Use in Children at Risk for AKI. Kidney International Reports. 2025; 10:4241-4251.
Malaria associated pathogenesis of chronic kidney disease (MAP-CKD): a prospective study of children hospitalized with severe malaria. BMC Nephrology. 2025; 26:390.
Transdermal Measurement Detects GFR Changes During Cardiopulmonary Bypass (CPB): A Preclinical Ovine Study. Journal of the American Society of Nephrology : JASN. 2025; 36:10.1681/asn.2025gsh1d3gt.
Long-term follow-up strategies for children after severe acute kidney injury. Pediatric Research. 2025; 98:1426-1435.
Clinical Study Evaluating Accuracy of the Transdermal (GFR) Methodology in Patients with CKD. Journal of the American Society of Nephrology : JASN. 2025; 36:10.1681/asn.20255eh92t8x.
Evaluating Real-World Data of CRRT Dose Prescription: Results from the CRRTnet Registry. Journal of the American Society of Nephrology : JASN. 2025; 36:10.1681/asn.2025d59f348f.
Temporal Machine-Learning Model for Predicting Seven-Day RRT-Free Survival in Critically Ill Patients on Continuous Renal Replacement Therapy. Journal of the American Society of Nephrology : JASN. 2025; 36:10.1681/asn.202527qe0ybg.
From the Blog
First Acute Kidney Injury Diagnostic Test Wins FDA Clearance
Stuart L. Goldstein, MD, FAAP, FNKF, Prasad Devarajan, MD12/7/2023
For Continuous Dialysis Nafamostat Shows Similar Efficacy, Lower Toxicity, Lower Costs vs. Citrate
Stuart L. Goldstein, MD, FAAP, FNKF4/5/2022
Better AWAREness of Acute Kidney Injury Could Transform Intensive Care
Stuart L. Goldstein, MD, FAAP, FNKF6/30/2019
7 Things Parents Need To Know About Nephrotoxic Medications
3/10/2016
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey